Targeting Programmed Death-1 (PD-1) and Its Ligand (PD-L1) | Personalized Medicine in Oncology
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial - The Lancet Oncology
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial - The Lancet Oncology
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006 - Annals of Oncology
IJMS | Free Full-Text | Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials | HTML
How Combination Therapy Works | OPDIVO® (nivolumab) + YERVOY® (ipilimumab)
Frontiers | The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study | Oncology
Special Issues | Value-Based Cancer Care
Ipilimumab: Mode of Action Note. From " Ipilimumab: Controversies in... | Download Scientific Diagram
Ipilimumab - Yervoy blijkt veilige en effectieve behandeling bij beginnende nog niet behandelde patienten met een melanoom.
References in Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) - The Lancet
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors - European Urology
Mechanism of Action of Yervoy & Opdivo | BioSerendipity
Ipilimumab – mechanism of action and impact on advanced melanoma - ppt download
Mechanism of action of the immune checkpoint inhibitors currently under... | Download Scientific Diagram
New modalities of cancer treatment for NSCLC: focus on immunotherapy | CMAR
Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma | Future Oncology
Mechanism of Pembrolizumab / Nivolumab. (Reprinted from permission of... | Download Scientific Diagram
Synergism between CTLA-4 and PD-(L)1 inhibition: the nivolumab-ipilimumab story - BJMO
Nivolumab Overview - Creative Biolabs
Ipilimumab - Yervoy blijkt veilige en effectieve behandeling bij beginnende nog niet behandelde patienten met een melanoom.
Targets and action of ICIs ipilimumab, nivolumab, and pembrolizumab: A.... | Download Scientific Diagram
Mechanism of Pembrolizumab / Nivolumab. (Reprinted from permission of... | Download Scientific Diagram
IJMS | Free Full-Text | Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials | HTML
Ipilimumab – mechanism of action and impact on advanced melanoma - ppt download
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors | SpringerLink
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial - The Lancet Oncology
Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab - ScienceDirect
